236 related articles for article (PubMed ID: 25000969)
21. Synthesis and biological evaluation of negative allosteric modulators of the Kv11.1(hERG) channel.
Yu Z; van Veldhoven JP; 't Hart IM; Kopf AH; Heitman LH; IJzerman AP
Eur J Med Chem; 2015 Dec; 106():50-9. PubMed ID: 26519929
[TBL] [Abstract][Full Text] [Related]
22. A novel structure-based virtual screening model for the hERG channel blockers.
Du L; Li M; You Q; Xia L
Biochem Biophys Res Commun; 2007 Apr; 355(4):889-94. PubMed ID: 17331468
[TBL] [Abstract][Full Text] [Related]
23. Role of the pH in state-dependent blockade of hERG currents.
Wang Y; Guo J; Perissinotti LL; Lees-Miller J; Teng G; Durdagi S; Duff HJ; Noskov SY
Sci Rep; 2016 Oct; 6():32536. PubMed ID: 27731415
[TBL] [Abstract][Full Text] [Related]
24. Inhibitory effects of a bisbenzylisoquinline alkaloid dauricine on HERG potassium channels.
Zhao J; Lian Y; Lu C; Jing L; Yuan H; Peng S
J Ethnopharmacol; 2012 Jun; 141(2):685-91. PubMed ID: 21920426
[TBL] [Abstract][Full Text] [Related]
25. The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o.
Diaz GJ; Daniell K; Leitza ST; Martin RL; Su Z; McDermott JS; Cox BF; Gintant GA
J Pharmacol Toxicol Methods; 2004; 50(3):187-99. PubMed ID: 15519905
[TBL] [Abstract][Full Text] [Related]
26. A critical assessment of combined ligand- and structure-based approaches to HERG channel blocker modeling.
Du-Cuny L; Chen L; Zhang S
J Chem Inf Model; 2011 Nov; 51(11):2948-60. PubMed ID: 21902220
[TBL] [Abstract][Full Text] [Related]
27. A systematic methodology for large scale compound screening: A case study on the discovery of novel S1PL inhibitors.
Deniz U; Ozkirimli E; Ulgen KO
J Mol Graph Model; 2016 Jan; 63():110-24. PubMed ID: 26724452
[TBL] [Abstract][Full Text] [Related]
28. Calculation of absolute binding free energies between the hERG channel and structurally diverse drugs.
Negami T; Araki M; Okuno Y; Terada T
Sci Rep; 2019 Nov; 9(1):16586. PubMed ID: 31719645
[TBL] [Abstract][Full Text] [Related]
29. The interactions between hERG potassium channel and blockers.
Du L; Li M; You Q
Curr Top Med Chem; 2009; 9(4):330-8. PubMed ID: 19442204
[TBL] [Abstract][Full Text] [Related]
30. The synergic modeling for the binding of fluoroquinolone antibiotics to the hERG potassium channel.
Ryu S; Imai YN; Oiki S
Bioorg Med Chem Lett; 2013 Jul; 23(13):3848-51. PubMed ID: 23711922
[TBL] [Abstract][Full Text] [Related]
31. Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG1 pore domain.
Durdagi S; Duff HJ; Noskov SY
J Chem Inf Model; 2011 Feb; 51(2):463-74. PubMed ID: 21241063
[TBL] [Abstract][Full Text] [Related]
32. Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties.
Polak S; Wiśniowska B; Brandys J
J Appl Toxicol; 2009 Apr; 29(3):183-206. PubMed ID: 18988205
[TBL] [Abstract][Full Text] [Related]
33. Human ether-a-go-go-related gene channel blockers and its structural analysis for drug design.
Narayana Moorthy NS; Ramos MJ; Fernandes PA
Curr Drug Targets; 2013 Jan; 14(1):102-13. PubMed ID: 23061466
[TBL] [Abstract][Full Text] [Related]
34. Revealing the structural basis of action of hERG potassium channel activators and blockers.
Perry M; Sanguinetti M; Mitcheson J
J Physiol; 2010 Sep; 588(Pt 17):3157-67. PubMed ID: 20643767
[TBL] [Abstract][Full Text] [Related]
35. Computational investigations of hERG channel blockers: New insights and current predictive models.
Villoutreix BO; Taboureau O
Adv Drug Deliv Rev; 2015 Jun; 86():72-82. PubMed ID: 25770776
[TBL] [Abstract][Full Text] [Related]
36. Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.
Zachariae U; Giordanetto F; Leach AG
J Med Chem; 2009 Jul; 52(14):4266-76. PubMed ID: 19534531
[TBL] [Abstract][Full Text] [Related]
37. Common pharmacophores for uncharged human ether-a-go-go-related gene (hERG) blockers.
Aronov AM
J Med Chem; 2006 Nov; 49(23):6917-21. PubMed ID: 17154521
[TBL] [Abstract][Full Text] [Related]
38. Altering extracellular potassium concentration does not modulate drug block of human ether-a-go-go-related gene (hERG) channels.
Limberis JT; Su Z; Cox BF; Gintant GA; Martin RL
Clin Exp Pharmacol Physiol; 2006 Nov; 33(11):1059-65. PubMed ID: 17042915
[TBL] [Abstract][Full Text] [Related]
39. Global analysis reveals families of chemical motifs enriched for HERG inhibitors.
Du F; Babcock JJ; Yu H; Zou B; Li M
PLoS One; 2015; 10(2):e0118324. PubMed ID: 25700001
[TBL] [Abstract][Full Text] [Related]
40. Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37 degrees C: Cisapride versus dofetilide.
Milnes JT; Witchel HJ; Leaney JL; Leishman DJ; Hancox JC
J Pharmacol Toxicol Methods; 2010; 61(2):178-91. PubMed ID: 20172036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
